CY1117487T1 - Ετεροκυκλικες ενωσεις και οι χρησεις τους - Google Patents

Ετεροκυκλικες ενωσεις και οι χρησεις τους

Info

Publication number
CY1117487T1
CY1117487T1 CY20161100347T CY161100347T CY1117487T1 CY 1117487 T1 CY1117487 T1 CY 1117487T1 CY 20161100347 T CY20161100347 T CY 20161100347T CY 161100347 T CY161100347 T CY 161100347T CY 1117487 T1 CY1117487 T1 CY 1117487T1
Authority
CY
Cyprus
Prior art keywords
inflammatory
acute
arthritis
diseases
treatment
Prior art date
Application number
CY20161100347T
Other languages
English (en)
Inventor
Minna Hue Thanh Bui
Timothy D Cushing
Lopez De Turiso Felix Gonzalez
Xiaolin Hao
Brian Lucas
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of CY1117487T1 publication Critical patent/CY1117487T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Υποκατεστημένα δικυκλικά ετεροαρύλια και συνθέσεις που τα περιέχουν, για τη θεραπεία γενικής φλεγμονής, αρθρίτιδας, ρευματικών ασθενειών, οστεοαρθρίτιδας, φλεγμονωδών εντερικών διαταραχών, φλεγμονωδών οφθαλμικών διαταραχών, φλεγμονωδών ή ασταθών διαταραχών της ουροδόχου κύστης, ψωρίασης, δερματοπαθειών με φλεγμονώδη συστατικά, χρονιών φλεγμονωδών καταστάσεων που περιλαμβάνουν αλλά δεν περιορίζονται σε αυτοάνοσες ασθένειες όπως συστηματικό ερυθηματώδη λύκο (SLE), βαριά μυασθένεια, ρευματοειδή αρθρίτιδα, οξεία διάχυτη εγκεφαλομυελίτιδα, ιδιοπαθή θρομβοκυτταροπενική πορφύρα, πολλαπλή σκλήρυνση, σύνδρομο Sjoergen και αυτοάνοση αιμολυτική αναιμία, αλλεργικές καταστάσεις που περιλαμβάνουν όλες τις μορφές υπερευαισθησίας. Η παρούσα εφεύρεση επίσης καθιστά δυνατές μεθόδους για θεραπεία καρκίνων που οφείλονται σε, εξαρτώνται από ή σχετίζονται με δραστικότητα ρ 110, που περιλαμβάνουν αλλά δεν περιορίζονται σε λευχαιμίες, όπως οξεία μυελοειδή λευχαιμία (AML), μυελοδυσπλαστικό σύνδρομο (MDS), μυελοπολλαπλασιαστικές ασθένειες (MPD) χρόνια μυελοειδή λευχαιμία (CML). οξεία λεμφοβλαστική λευχαιμία Τ-κυττάρων (T-ALL), οξεία λεμφοβλαστική λευχαιμία Β-κυττάρων (Β-ALL), μη Hodgkin λέμφωμα (NHL), λέμφωμα Β κυττάρων και συμπαγείς όγκους, όπως καρκίνο του μαστού.
CY20161100347T 2012-04-04 2016-04-26 Ετεροκυκλικες ενωσεις και οι χρησεις τους CY1117487T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261620270P 2012-04-04 2012-04-04
EP13717655.8A EP2834231B1 (en) 2012-04-04 2013-04-04 Heterocyclic compounds and their uses

Publications (1)

Publication Number Publication Date
CY1117487T1 true CY1117487T1 (el) 2017-04-26

Family

ID=48142975

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100347T CY1117487T1 (el) 2012-04-04 2016-04-26 Ετεροκυκλικες ενωσεις και οι χρησεις τους

Country Status (31)

Country Link
US (2) US8716290B2 (el)
EP (1) EP2834231B1 (el)
JP (1) JP2015512451A (el)
KR (1) KR20140139547A (el)
CN (1) CN104395305A (el)
AP (1) AP3611A (el)
AU (1) AU2013243506A1 (el)
CA (1) CA2869413A1 (el)
CL (1) CL2014002686A1 (el)
CO (1) CO7091181A2 (el)
CR (1) CR20140503A (el)
CY (1) CY1117487T1 (el)
DK (1) DK2834231T3 (el)
EA (1) EA201491823A1 (el)
ES (1) ES2577109T3 (el)
HR (1) HRP20160352T1 (el)
HU (1) HUE028762T2 (el)
IL (1) IL234822A0 (el)
MA (1) MA37472A1 (el)
ME (1) ME02473B (el)
MX (1) MX2014011970A (el)
PE (1) PE20142457A1 (el)
PH (1) PH12014502246A1 (el)
PL (1) PL2834231T3 (el)
RS (1) RS54716B1 (el)
SG (1) SG11201406316VA (el)
SI (1) SI2834231T1 (el)
SM (1) SMT201600211B (el)
TN (1) TN2014000412A1 (el)
WO (1) WO2013152150A1 (el)
ZA (1) ZA201407037B (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765768B2 (en) * 2010-11-17 2014-07-01 Amgen Inc. Heterocyclic compounds and their uses
DK2834231T3 (en) * 2012-04-04 2016-04-18 Amgen Inc HETEROCYCLIC COMPOUNDS AND THEIR USES
AR100289A1 (es) 2014-05-06 2016-09-21 Amgen Inc Formas de un inhibidor de pi3k
CU24428B1 (es) 2014-07-04 2019-06-04 Lupin Ltd Derivados de quinolizinona como inhibidores de pi3k
US9637488B2 (en) 2015-01-29 2017-05-02 Fuqiang Ruan Heterocyclic compounds as inhibitors of class I PI3KS
CA3013490C (en) * 2016-03-05 2021-09-14 Hangzhou Zhengxiang Pharmaceuticals Co., Ltd. Quinoline analogs as phosphatidylinositol 3-kinase inhibitors
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US6043062A (en) 1995-02-17 2000-03-28 The Regents Of The University Of California Constitutively active phosphatidylinositol 3-kinase and uses thereof
GB9611460D0 (en) 1996-06-01 1996-08-07 Ludwig Inst Cancer Res Novel lipid kinase
US5858753A (en) 1996-11-25 1999-01-12 Icos Corporation Lipid kinase
US5822910A (en) 1997-10-02 1998-10-20 Shewmake; I. W. Fishing line tensioning device
DE602005015110D1 (de) * 2004-06-28 2009-08-06 Bayer Schering Pharma Ag 4,6-disubstitutierte pyrimidine und deren verwendung als proteinkinase-hemmer
RS53151B (en) * 2007-03-23 2014-06-30 Amgen Inc. 3-SUBSTITUTED QUINOLINE OR QUINOXALINE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR (PI3K)
ES2587738T3 (es) * 2007-12-21 2016-10-26 Ucb Biopharma Sprl Derivados de quinoxalina y quinolina como inhibidores de quinasa
CA2745280A1 (en) * 2008-12-04 2010-06-10 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
AU2010265974B2 (en) * 2009-06-25 2014-09-11 Amgen Inc. Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases
US8633313B2 (en) * 2009-12-18 2014-01-21 Amgen Inc. Heterocyclic compounds and their uses
CA2803624A1 (en) * 2010-07-02 2012-01-05 Jason A. Duquette Heterocyclic compounds and their use as inhibitors of pi3k activity
DK2834231T3 (en) * 2012-04-04 2016-04-18 Amgen Inc HETEROCYCLIC COMPOUNDS AND THEIR USES

Also Published As

Publication number Publication date
CO7091181A2 (es) 2014-10-21
EA201491823A1 (ru) 2015-01-30
HRP20160352T1 (hr) 2016-05-06
PE20142457A1 (es) 2015-02-07
CL2014002686A1 (es) 2015-05-08
CN104395305A (zh) 2015-03-04
KR20140139547A (ko) 2014-12-05
AU2013243506A1 (en) 2014-10-09
ME02473B (me) 2017-02-20
ES2577109T3 (es) 2016-07-13
WO2013152150A1 (en) 2013-10-10
US20140206694A1 (en) 2014-07-24
EP2834231A1 (en) 2015-02-11
CA2869413A1 (en) 2013-10-10
RS54716B1 (en) 2016-08-31
PL2834231T3 (pl) 2016-07-29
US8835432B2 (en) 2014-09-16
SMT201600211B (it) 2016-08-31
AP3611A (en) 2016-02-29
EP2834231B1 (en) 2016-03-30
HUE028762T2 (en) 2016-12-28
AP2014007979A0 (en) 2014-09-30
SI2834231T1 (sl) 2016-09-30
US20130267524A1 (en) 2013-10-10
TN2014000412A1 (en) 2015-12-21
PH12014502246A1 (en) 2014-12-15
CR20140503A (es) 2015-03-06
MX2014011970A (es) 2015-05-12
US8716290B2 (en) 2014-05-06
ZA201407037B (en) 2015-11-25
JP2015512451A (ja) 2015-04-27
MA37472A1 (fr) 2016-09-30
SG11201406316VA (en) 2014-11-27
IL234822A0 (en) 2014-12-31
DK2834231T3 (en) 2016-04-18

Similar Documents

Publication Publication Date Title
CY1117487T1 (el) Ετεροκυκλικες ενωσεις και οι χρησεις τους
EA201270013A1 (ru) Гетероциклические соединения и их применение
EA201291005A1 (ru) Гетероциклические соединения и их применение
MX2013007261A (es) Compuestos heterociclicos y sus usos.
MX2012015134A (es) Compuestos heterociclicos y su uso como inhibidores de actividad de pi3k.
MX2012015135A (es) Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k.
MX2011013666A (es) Compuestos heterociclicos y sus usos.
MX2009009968A (es) Compuestos heterociclicos y sus usos.
MX2011013667A (es) Compuestos heterociclicos y sus usos.
MX2009009913A (es) Derivados de quinolina o benzopirazina y sus usos para el tratamiento de enfermedades inflamatorias, enfermedades autoinmunitarias o varias clases de canceres.
MX2012015143A (es) Compuestos heterociclicos que contienen nitrogeno como inhibidores de pi3k delta.
MX2011013901A (es) Derivados de 4h-pirido [1,2-a] pirimidin-4-ona como inhibidores de pi3k.
MX2012015147A (es) Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k.
MX2009010050A (es) Derivados de quinolina o quinoxalina 3-sustituidos y su uso como inhibidores de fosfotidilinositol 3-cinasa (p13k).
CL2013003073A1 (es) Compuestos derivados de pirrolotriazinona o imidazotriazinona, inhibidores de pi3k; composicion farmaceutica que los comprende; combinacion farmaceutica; utiles en el tratamiento de enfermedades respiratorias, inflamatorias, autoinmune, neurologica, cancer, entre otras.
EA201990048A1 (ru) [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИДИНИЛ-ЗАМЕЩЕННЫЕ ИНДОЛЬНЫЕ СОЕДИНЕНИЯ
MX2017000331A (es) Compuestos de aminopiridazinona como inhibidores de quinasas de proteina.
EA201691361A1 (ru) Антитела к lag-3 для лечения гематологических злокачественных опухолей
MX2016001018A (es) Composiciones estabilizadas de anticuerpos.
EA201790543A1 (ru) Способы лечения заболевания или расстройства с использованием составов для перорального применения, содержащих аналоги цитидина, в комбинации с моноклональным антителом к pd1 или pdl1
EA201492250A1 (ru) Гетероциклическое соединение
MX2016014483A (es) Nuevos compuestos utiles como inhibidores de s100.
CY1117196T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
AR090705A1 (es) Compuestos de piridina y pirimidina y sus usos como inhibidores de fosfatidilinositol 3-quinasa (pi3k)
CY1114775T1 (el) Παραγωγα 3-υποκατεστημενης κινολινης ή κινοξαλινης και η χρηση τους ως αναστολεων της 3-κινασης φωσφατιδυλινοσιτολης (ρι3κ)